Dabigatran (Pradaxa) is best used for which of the following patient scenarios?

• A. CVA patient with history of TIA
• B. DVT prophylaxis after hip surgery
• C. Prophylaxis for emboli in AFIB 2/2 aortic stenosis
• D. Prophylaxis for emboli in AFIB 2/2 non-valvular cause

Answer: (D)

Dabigatran is a direct oral anticoagulant designed to reduce stroke and systemic embolism in patients with nonvalvular atrial fibrillation. In nonvalvular AF, the atria can develop clots due to stasis, and anticoagulation lowers the risk of these clots traveling to the brain or other organs. Dabigatran offers a convenient alternative to warfarin because it has predictable effects and usually doesn’t require regular INR monitoring. It is not used for valvular AF, such as AF associated with mechanical heart valves or significant rheumatic disease, where DOACs are not recommended. It’s also not the first choice for postoperative DVT prophylaxis after hip surgery, where other agents are typically preferred. Therefore, the scenario best matching dabigatran’s use is embolic prophylaxis in nonvalvular atrial fibrillation. Keep in mind kidney function matters, since dabigatran is largely cleared by the kidneys and dosing adjustments or avoidance may be needed with renal impairment.